作为泛BETBD2-首选抑制剂的宏环二胺类同类
Jiewei Jiang1, Taimeng Liang2, Jonathan Solberg1
1Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street, MN, 55414, USA.
一个二皮里多皮里米丁乙烯乙烯的宏环化增强了原蛋白和额外终端 (BET) 蛋白的亲和力和选择性. 这一策略改善了对BET原蛋白2的结合,证明了针对癌症向治疗的潜力.
科学领域:
- 药用化学 医学化学
- 化学生物学 化学生物学
- 药物发现 药物发现 药物发现
背景情况:
- 原体和额外终端 (BET) 蛋白质是表观遗传调节剂,涉及到各种癌症.
- 开发选择性BET抑制剂对于向癌症治疗至关重要.
- 化合物1,二二二胺基乙乙,作为结构修改的起点.
研究的目的:
- 合成和评估化合物1的宏环类型,以增强BET蛋白的亲和力和选择性.
- 为了研究减少形状灵活性对抑制剂结合的影响.
- 探索这些化合物作为抗癌剂的潜力.
主要方法:
- 合成14种基于二二二胺基乙烯 Ester 支架的宏环类类似物.
- 光极化 (FP) 测试以确定对BRDT-1和BRD4-1的结合亲和力 (Ki).
- 差分扫描光测量 (DSF) 和蛋白观测的NMR,以评估与特定的类基因 (BD1,BD2) 的结合.
- 进行BROMOscan和bromoMAX测试以评估跨多个类域的选择性.
- 使用BRD4-1.选择的抑制剂的共同晶体结构的确定.
- 在体外评估使用MM.1S癌细胞系的抗癌活性.
主要成果:
- 化合物6b和6d对BRDT-1和BRD4-1.具有强烈的亲和力.
- 宏循环治疗显著增加了BET代蛋白2 (BRDT-2) 的结合亲和力和选择性.
- 共同晶体结构揭示了抑制剂构造,并建议BD2选择性的机制,涉及Pi堆积和H键与保存的His残留物.
- 化合物6d显著抑制了MM.1S癌细胞生长 (IC50 = 2.6μM).
结论:
- 宏循环化策略有效地限制了形状灵活性,从而提高了BET原体的亲和力和选择性,特别是BD2.
- 开发的化合物,特别是6d,显示出作为选择性BET抑制剂用于癌症治疗的前景.
- 这项研究强调了宏循环化在优化药物向相互作用和实现选择性的有用性.
更多相关视频
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Thiazide-Class Diuretics
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Direct Renin Inhibitors
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
